Menu
Positive Bioscience
India's Leading Cancer Testing Company
  • Home
  • Patients
    • Bladder Cancer
    • Blood Cancer
    • Breast Cancer
    • Bone Cancer
    • Colorectal Cancer
    • Liver Cancer
    • Lung Cancer
    • Melanoma
    • Oral Cancer
    • Ovarian Cancer
    • Pancreatic Cancer
    • Prostate Cancer
    • Testicular Cancer
    • Head and Neck Cancer
  • Tests
    • Myriad Genetics
      • BRACAnalysis
      • EndoPredict
      • myChoice CDx
      • MyRisk
      • Prolaris
    • PositiveSelect
      • PositiveSelect Lite
      • PositiveSelect Match
      • PositiveSelect Plus
      • PositiveSelect Ultimate
      • PositiveSelect Colorectal
      • PositiveSelect Lung
      • PositiveSelect Immunotherapy
  • Knowledge
  • Links
    • About
    • Publications
    • Press
    • Careers
    • Contact Us
  • Call Now
  • WhatsApp
Close Menu
Cancer Immunotherapy
September 11, 2020

Approaches for Tumor Mutation Burden estimation

Positive Bioscience

A robust, effective and clinically verifiable biomarker in multiple cancer types.

Approaches for Tumor Mutation Burden estimation 2

TMB Harmonization Project Overview (https://www.focr.org/tmb)

Immunotherapy has been approved as a first-line of treatment for several cancers, and may also be an effective treatment for patients with certain cancers that are resistant to prior treatment. However, immunotherapy doesn’t always work for every patient. Thus selection of patients on independent predictor of response such as TMB (Tumor Mutational Burden) becomes crucial across various cancer types.

TMB has incredible potential to be the key that unlocks the door for personalized therapy in oncology. The TMB of a tumor sample is calculated by the number of non-synonymous somatic mutations (single nucleotide variants and small insertions/deletions) per megabase in coding regions. Earlier studies have found a remarkable association between TMB values and the production of neo-antigen peptides and it is illustrated to be highly correlated with tumor immune response. TMB represents both the stability level of the tumor genome and heterogeneity of the tumor microenvironment. The potential of TMB as a pan-cancer predictive signature was an incredibly exciting prospect, and bringing it into routine clinical practice so the right patient at the right time can benefit from immunotherapy has always been the dogma of precision medicine. However, methods to calculate TMB varied greatly in scientific research and clinical practice. 

In clinical diagnostic setup, different testing methodologies and reporting strategies add confusion to trial enrollment, create chaos to clinical practice and in the worst case lead to the wrong conclusion at the point of patient care. 

For TMB in research, the most common method used is WES (Whole Exome Sequencing), which sequences only the coding regions of the genome, with average coverage of 120X to 150X. WES allows comprehensive measurement of TMB and is considered to be the gold standard. Initial studies showing a correlation between TMB and enhanced response to immunotherapy were based on WES datasets for TMB quantification. Despite the proven utility of WES in measuring TMB and predicting response to PD-1/PD-L1 blockade, it has many limitations. WES is expensive, time consuming, and labor intensive, and, therefore, difficult to incorporate into clinical practice. 

ALSO READ:  BRCA Testing for Prostate Cancer

In clinical application, targeted enrichment panels (gene panels) of various genomic sizes are routinely used to estimate TMB. Although only a small number of genes (about 300–500) are covered, gene panel sequences can identify rare somatic mutations because of the higher sequencing depth compared to WES. However, differences in panel size, gene coverage, library construction, sequencing, in addition to the underlying bioinformatics pipelines, are known drivers of variability in TMB estimates across laboratories.

Variability of TMB estimates across different panels and lack of robust predictive cutoffs,  were prime hindrance to adopt TMB as a biomarker in clinical practice. This led to the ‘ TMB Harmonization Consortium’, which began in late 2017 to address these challenges head on, anticipating the success of TMB as a predictive biomarker for immunotherapy across multiple tumor types.

The main challenge for accurate panel-based TMB quantification was the ability to extrapolate the global mutational burden from the narrow sequencing space targeted by a gene panel. This was overcome by  determining the concordance between panel-based and WES-based TMB, which is considered the reference for TMB quantification. Calibration methods using samples derived from The Cancer Genome Atlas (TCGA), which became a viable approach to aligning TMB scores. Further, variation across panels using patient formalin-fixed paraffin-embedded (FFPE) tissue samples were analysed. This empirical analysis compared panel TMB results to an agreed universal reference standard, consisting of a collection of human tumor-derived reference cell lines that span a clinically meaningful TMB dynamic range. Lastly in a retrospective clinical study, samples from patients treated with immunotherapy were evaluated to determine optimal TMB cut-offs for treatment decisions.

ALSO READ:  Breast Cancer: Enter Personalized Medicine

Several gene panels are being optimized to estimate TMB at reduced sequencing costs, and emerging evidence supports the feasibility of TMB quantification from liquid biopsies. Even an accurate TMB value is an imperfect predictor of immunotherapy response and further studies are needed to enhance its value as clinically useful immunotherapy biomarker. Integration of TMB with other potential immunotherapy biomarkers represents a promising way to refine prediction of immunotherapy responders. 

-By Fatma

Sources:

https://jitc.biomedcentral.com/articles/10.1186/s40425-019-0647-4

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6510391/#:~:text=TMB%20of%20a%20tumor%20sample,of%20the%20tumor%20micro%2Denvironment.

https://jitc.bmj.com/content/8/1/e000147

https://www.cancerresearch.org/immunotherapy/what-is-immunotherapy

https://www.foundationmedicine.com/blog/the-future-of-tmb-as-a-predictor-of-immunotherapy-response-depends-on-harmonization

https://mct.aacrjournals.org/content/molcanther/16/11/2598.full.pdf

Image source: https://www.focr.org/tmb

Chadwick Boseman’s Demise: A reminder of changing landscape in Colorectal cancers Immunotherapy in Gynaecological cancers

Related Posts

Cancer Care in India during COVID-19

Cancer Treatment

Cancer Care in India during COVID-19

Gynaecological Cancer awareness

Cancer Treatment

Immunotherapy in Gynaecological cancers

Immunotherapy Pancancer -TMB

Cancer Treatment

Immunotherapy Pan cancer-TMB

Search

Filter Posts

Back To Top
Positive Bioscience
© Positive Biosciences Limited 2021. All rights reserved. Disclaimer: Use for educational and informative purposes only. Omissions, errors and incomplete representations are possible. Information has been created to assist non-medical professionals and may be condensed or not fully represented. All information is subject to change without notice and information may not be up to date. The opinions and views in blogs on this website are from their author(s) may not be representative of Positive Biosciences Ltd. Positive Biosciences Ltd. makes absolutely no representations to the accuracy of the information presented here, strongly advises independent verification of all facts and cannot be held accountable for any damages whatsoever. Before making any decision(s) a qualified medical professional must be consulted. Information or consultations from Positive Biosciences Ltd. does not qualify as advise from a medical professional. All brands, tests, guidelines, products, company names, etc. are property of their respective owner(s). Positive Biosciences Ltd. may or may not associated with any study, publication, etc. referenced in any capacity and assumes no responsibility for external references, including any web links to third party pages.

Learn from the Experts

  • Cancer Care in India during COVID-19
  • Immunotherapy in Gynaecological cancers
  • Approaches for Tumor Mutation Burden estimation

Links

Jobs Opportunities

Privacy Policy

Terms & Conditions

Disclaimer